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1 Available anticancer drugs do not seem to modify the prognosis of metastatic melanoma.
Salicylate and acetyl salicylic acid (aspirin) were found to suppress growth in a number of transformed
cells, that is, prostate and colon. Therefore, we studied the direct effects of aspirin on metastatic B16
melanoma cells.
2 Aspirin at a plasma-attainable and nontoxic level suppressed the proliferation of B16 cells.
3 Aspirin induced the activation of p38 and c-Jun N-terminal kinase (JNK) mitogen-activated
protein kinases.
4 Inhibition of JNK, but not p38, decreased the suppressive effect of aspirin upon the
proliferation of B16 cells.
5 The aspirin-induced reduction in B16 proliferation was cumulative over time.
6 Aspirin and the chemotherapeutic drug 1,3-bis(2-chloroethyl)-1-nitrosourea
(BCNU) induced B16 cell death synergistically.
7 In addition to the murine B16 cell line, the proliferation of SK-28 human melanoma
cells was also suppressed by aspirin.
8 In conclusion, aspirin suppresses the proliferation of metastatic B16 cells in a JNK-dependent
mechanism.
British Journal of Pharmacology (2003) 138, 1156–1162. doi:10.1038/sj.bjp.705163
Keywords: MAPK; melanoma; aspirin; BCNU; p38; JNK
Abbreviations: BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; ECL, enhanced chemiluminescence reagent; JNK, c-Jun N-terminal
kinase; MAPK, mitogen-activated protein kinases; SDS-PAGE, sodium dodecylsulfate-polyacrylamide gel
electorphoresis
Introduction
The incidence of cutaneous malignant melanoma is increasing
and it is projected that Americans born in the year 2000 will
have a one in 75 lifetime risk of developing melanoma. Long-
term survival for patients with metastatic disease is only 5%
and the commonly used anticancer drugs do not seem to
modify the prognosis of metastatic disease (Brown & Nelson,
1999; Serrone & Hersey, 1999). Thus, new chemotherapeutic
agents for melanoma are of great clinical interest.
A significant decrease in the relative risk of malignant
melanoma was observed in women taking aspirin (Harris et al.,
2001). We have recently shown that incubation with acetyl
salicylic acid (aspirin) for 3 days reduced cellular proliferation
by up to 35–55% in prostate cancer cell lines (Rotem et al.,
2000), and that salicylic acid suppressed the proliferation of
various types of human cancer cells (Fingrut & Flescher,
2002). Therefore, we studied the effects of aspirin on
melanoma cells.
The mechanism through which aspirin affects the prolifera-
tion and viability of different cells is not clear. Mitogen-
activated protein kinases (MAPK) are proline-directed serine–
threonine kinases that are activated by upstream dual
specificity kinases which produce a simultaneous phosphor-
ylation on threonine and tyrosine residues. The p38 kinase and
c-Jun N-terminal kinase (JNK) comprise a subfamily of
MAPK that are strongly activated by stress signals (Robinson
& Cobb, 1997). Sodium salicylate was found to induce p38
activation in human fibroblasts and in green monkey kidney
cells (Schwenger et al., 1997, 1998). The activation of p38
resulted in apoptosis (Schwenger et al., 1997). In addition,
sodium salicylate and aspirin induced JNK activation in green
monkey kidney cells and in colon adenocarcinoma human cells
(Schwenger et al., 1999). Consequently, we evaluated the
involvement of the stress-responsive MAPK in the effects of
aspirin on melanoma cells.
Methods
Cells and reagents
The B16-F10.9 cell line used in this study is a metastatic
variant of the B16 murine melanoma (Hart, 1979). It was
grown in DMEM with 10% FCS. SK-28 are human melanoma
cells grown in RPMI-1640 with 10% FCS (ATCC, Rockville,
MD, U.S.A.).*Author for correspondence; E-mail: flascher@post.tau.ac.il
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All the reagents used were purchased from Sigma Chemicals
(St Louis, MO, U.S.A.) unless otherwise stated. SB203580 (a
specific p38 inhibitor that does not inhibit the activity of other
MAPK, Turchi et al., 2000) and SB202190 (an agent that
inhibits both JNK and p38, Turchi et al., 2000) were purchased
from Calbiochem (La Jolla, CA, U.S.A.). 1,3-Bis(2-chlor-
oethyl)-1-nitrosourea (BCNU) is a chemotherapeutic drug.
Cytotoxicity and cellular proliferation assays
Cellular proliferation and its inhibition were determined by the
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation
Assay (Promega, Madison, WI, U.S.A.). Upon completion
of a given experiment, MTS (a tetrazolium compound) at
333 mgml1+phenazine methosulfate (at 25mm) were added to
each well of the 96-well plate for 1 h at 371C. This allowed for
the development of the reaction in which dehydrogenases
reduce the MTS in metabolically active cells. Since the cells
were not washed before the addition of MTS, we did not have
any problem with potentially loosely adherent melanoma cells.
The soluble MTS formazan product was measured at 490 nm
by the CERES 900 HDi ELISA reader (Bio-Tek Instruments,
Inc, Highland Park, VT, U.S.A.). Optical density is directly
proportional to the number of living cells in culture.
Cytotoxicity (%) was calculated in the following way: [(OD
of control cells OD of drug-treated cells)/OD of control
cells] 100. Since the same number of cells was aliquoted into
each well initially, decreased optical density in wells containing
treated cells reflects cellular death and/or decrease in the rate
of proliferation. To distinguish between these two possibilities,
we employed an additional cytotoxicity assay that detects cell
death by lack of trypan blue exclusion (see below).
Cell death was determined by trypan blue exclusion. Cells
were incubated with 0.1% trypan blue for 2–5min and the
percentage of dead cells (those which did not exclude the dye)
was determined microscopically.
Determination of p38 and c-Jun phosphorylation
For analysis of phospho-p38 (indicating p38 activation) levels,
and c-Jun phosphorylation (indicating JNK activity), whole-
cell lysates were prepared as described before (Samet et al.,
1998). Protein samples (50 mg of whole-cell lysate) were
separated by sodium dodecylsulfate-polyacrylamide gel elec-
torphoresis (SDS-PAGE) on 14% tris-glycine gels, followed by
immunoblotting using specific antibodies against phospho-p38
(1 : 1000, New England Biolabs, Cambridge, MA, U.S.A.) and
phosphorylated c-Jun (1:1000, Santa Cruz Biotechnology,
Santa Cruz, CA, U.S.A.), respectively, at 41C. Antigen –
antibody complexes were stained with HRP-conjugated anti-
body (1 : 2000, Bio-Rad, Richmond, CA, U.S.A.) and en-
hanced chemiluminescence reagent (ECL), and exposed to
ECL film (both from Amersham, Arlington Heights, IL,
U.S.A.). Immunoblot images were digitized and the optical
densities of specific antigen–antibody complexes were quanti-
fied using the Gene Gnome Imaging System supported by the
Gene Tools software package (both from Syngene, Frederick,
MD, U.S.A.). The phosphorylation of p38 and c-Jun was
determined following treatment with aspirin. No change in the
total levels of these proteins was detected in the same cultures.
Statistical analysis
The statistical significance of the results was determined
(where appropriate) by two-tailed Student’s t-test.
Results
Suppression of B16 proliferation by aspirin
Since the direct effect of aspirin on melanoma cells has never
been reported, we studied the ability of aspirin to modulate the
viability and proliferative potential of a metastatic variant of
B16 melanoma cells. Aspirin (at 0.5–5mm) suppressed the
ability of B16 cells to proliferate in a dose-dependent manner
(Figure 1). The validity of the enzymatic assay (Figure 1, panel
a), as a measure of cellular proliferation, was established by
direct cell counts (Figure 1, panel b). This outcome could be
the result of cell death. However, determining the fraction of
dead cells in our cultures (by the trypan blue exclusion
method), we did not find more than 5–10% dead cells in either
control or any of the aspirin-treated cultures. These results
Figure 1 Aspirin suppresses B16 cellular proliferation. (a) B16 cells
(at 4 103well1) were seeded in 96-well plates and allowed to
adhere overnight. Aspirin at the indicated concentrations was added
for 1 day. Optical density representing viable cells was determined
by the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation
Assay. (b) B16 cells (at 4 105well1) were seeded in six-well plates
and allowed to adhere overnight. Aspirin at the indicated
concentrations was added for 1 day. The number of viable cells
was determined by microscopic cell counts. Inhibition of prolifera-
tion is calculated as percentage of control cultures that were not
treated with aspirin, mean7s.d. The inhibition was statistically
significant at *Po0.025, **Po0.01, ***Po0.005 for panel a, and
*Po0.025, **Po0.005, ***Po0.0005 for panel b; n¼ 3.
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strongly suggest that the reduction in cell number, depicted in
Figure 1, reflects suppression of cellular proliferation rather
than cell death.
Mediation of aspirin-induced suppression of B16
proliferation by JNK, but not p38, MAPK
Since sodium salicylate was found to induce p38 activation in
human fibroblasts and green monkey kidney cells (Schwenger
et al., 1997, 1998), we investigated the possible involvement of
this stress-regulated kinase in the aspirin-induced suppression
of B16 proliferation. Upon exposure to aspirin at 3mm for 5–
60min, B16 cells exhibited a rise in the levels of activated p38
(Figure 2). The rise was maximal at 20min. While these results
clearly indicate an activation of p38 by aspirin in our system, a
cause and effect relation had to be investigated. To that end,
we employed a specific p38 inhibitor that does not affect other
MAPK-SB203580. This inhibitor belongs to a series of
pyridinyl-imidazole compounds that have a selective effect
on the p38 MAPK activity, while not exhibiting inhibition of
any other MAPK (JNK and ERK), protein kinase C and
cAMP-dependent kinase activities (Lee et al., 1994). SB203580
did not exhibit any effect on aspirin-induced suppression of
proliferation in B16 cells. On the other hand, SB202190 (an
inhibitor of both p38 and JNK, Turchi et al., 2000) inhibited
significantly, in a dose-dependent manner, the aspirin-induced
suppression of B16 cells (Figure 3). SB202190 by itself did not
affect B16 proliferation at the range of concentrations used
(0.5–4 mm). These results point towards JNK as the MAPK
that mediates the suppression of B16 proliferation induced by
aspirin. Indeed, we found that aspirin induced JNK activity in
B16 cells and that SB202190 decreased this effect (Figure 4).
B16 proliferation during prolonged exposure to aspirin
Aspirin at 3mm reduces B16 proliferation by approximately
30% (Figure 1). We prolonged the exposure to aspirin for 3
days and determined if the effect is cumulative. After 3 days in
the presence of aspirin at 3mm, the number of B16 cells was
reduced by about 63% in comparison with untreated cells
(Figure 5), suggesting that the suppressive effect of aspirin is
cumulative. Growing the cells for three additional days with
aspirin further decreased their number, reaching an inhibition
level of 91%. Similar to 1-day exposure, the effect of aspirin
during prolonged exposure was also on cell proliferation, but
did not cause cell death, as assessed by trypan blue exclusion.
When the aspirin was removed, the cells resumed their normal
rate of proliferation (data not shown).
Synergistic effect of aspirin and a chemotherapeutic drug
on B16 proliferation
To evaluate the efficiency of aspirin in enhancing the antic-
ancer effect of currently available chemotherapy, we deter-
mined the cytotoxic effect of aspirin+BCNU. BCNU is a
chemotherapeutic drug which has been shown to kill B16 cells
(Poo et al., 1997). As can be seen in Figure 6, aspirin and
BCNU acted synergistically (Po0.05) in exerting a cytotoxic
effect towards B16 cells. While aspirin by itself does not kill
B16 cells, we confirmed that the drug combination induced cell
death, by the trypan blue exclusion assay.
Proliferation of human melanoma cells (SK-28) in the
presence of aspirin
In order to evaluate the relevance of aspirin-induced suppres-
sion of cellular proliferation in the B16 murine system to
Figure 2 Aspirin induces p38 activation in B16 cells. B16 cells (at
4 105well1) were seeded in six-well plates and allowed to adhere
overnight. The cells were then treated with or without (0) aspirin at
3mm for the indicated periods of time. For analysis of phospho-p38
(indicating p38 activation) levels, whole-cell lysates were prepared
(Samet et al., 1998) and proteins were separated by SDS-PAGE,
followed by immunoblotting using specific antibodies against
phospho-p38. Antigen – antibody complexes were stained with
HRP-conjugated antibody and enhanced chemiluminescence re-
agent, and exposed to ECL film. Immunoblot images were digitized
and the optical densities of specific antigen-antibody complexes were
quantified. A typical experiment is shown, representing two
experiments with similar results.
Figure 3 The JNK and p38 inhibitor SB202190 decreases aspirin-
induced suppression of B16 cellular proliferation. B16 cells (at
4 103well1) were seeded in 96-well plates and allowed to adhere
overnight. Aspirin at 3mm was added for 1 day. SB202190 was
added at the indicated concentrations, 30min before the addition of
aspirin, and was removed 2.5 h afterwards. Optical density
representing viable cells was determined by the CellTiter 96 Aqueous
Non-Radioactive Cell Proliferation Assay. Inhibition of prolifera-
tion is calculated as percentage of control cultures that were not
treated with aspirin, mean7s.d. The effect of SB202190 (in
comparison with None¼ only aspirin) was statistically significant
at *Po0.05, **Po0.005, ***Po0.0005; n¼ 3.
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human cells, we determined the effect of aspirin on the human
cell line – SK-28. As can be seen in Figure 7, aspirin suppressed
the proliferation of SK-28 cells in a dose-dependent manner.
Discussion
The purpose of this study was to investigate for the first time
the direct effect of aspirin on melanoma cells and to explore its
mechanism. Using the B16-F10.9 metastatic melanoma cell
Figure 4 Aspirin induces JNK activity in B16 cells. B16 cells (at
4 105well1) were seeded in six-well plates and allowed to adhere
overnight. The cells were then treated with or without (0) aspirin at
3mm for the indicated periods of time. SB202190 (JNK inhibitor)
was added at 4 mm, 30min before the addition of aspirin. For
analysis of phospho-c-Jun levels (indicating JNK activity), whole-
cell lysates were prepared (Samet et al., 1998) and proteins were
separated by SDS-PAGE, followed by immunoblotting using
specific antibodies against phospho-c-Jun. Antigen–antibody com-
plexes were stained with HRP-conjugated antibody and enhanced
chemiluminescence reagent, and exposed to ECL film. Immunoblot
images were digitized and the optical densities of specific antigen–
antibody complexes were quantified. A typical experiment is shown,
representing two experiments with similar results.
Figure 5 Effect of prolonged exposure to aspirin on B16 prolifera-
tion. B16 cells (at 4 103well1) were seeded in 96-well plates and
allowed to adhere overnight. Aspirin at 3mm was added for 1 and 3
days. Optical density representing viable cells was determined by the
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay.
Cellular proliferation is calculated as percentage of control cultures
that were not treated with aspirin (defined as 100%), mean7s.d;
n¼ 3.
Figure 6 Cytotoxic effect of aspirin and BCNU towards B16 cells.
B16 cells (at 4 103well1) were seeded in 96-well plates and allowed
to adhere overnight. Aspirin at 1 and 3mm, and/or BCNU at 50 mm,
were added for 1 day. Optical density representing viable cells was
determined by the CellTiter 96 Aqueous Non-Radioactive Cell
Proliferation Assay. Cytotoxicity is calculated as percentage of
control cultures that were not treated, mean7s.d., n¼ 3. The
synergistic effect (the difference between cytotoxicity in the presence
of both drugs together, and the sum of the cytotoxicities of each
drug administered separately) was significant at Po0.05, for each
combination of aspirin and BCNU.
Figure 7 Aspirin suppresses SK-28 cellular proliferation. SK-28
cells (at 4 103well1) were seeded in 96-well plates and allowed to
adhere overnight. Aspirin at the indicated concentrations was added
for 1 day. Optical density representing viable cells was determined
by the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation
Assay. Inhibition of proliferation is calculated as percentage of
control cultures that were not treated with aspirin, mean7s.d. The
inhibition was statistically significant at *Po0.05, **Po0.005,
***Po0.0005; n¼ 3.
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line, we found that aspirin suppresses cellular proliferation
without killing the cells. The inhibitory effect of aspirin is
mediated through the activation of the JNK MAPK.
Prolonged exposure to aspirin produces a cumulative effect.
While aspirin does not kill the B16 cells by itself, it enhances
the cytocidal effect of BCNU synergistically. The antiproli-
ferative effect of aspirin is also exerted on the human
melanoma cells – SK-28.
Our novel finding that aspirin suppresses murine and human
melanoma cell proliferation is not unique in that aspirin was
found to exert the same effect on colon and prostate cancer
cells (Fulton, 1987; Ara & Teicher, 1996; Hanif et al., 1996;
Rotem et al., 2000). However, aspirin in the same range of
concentrations (0.25–4mm) did not interfere with the pro-
liferation of nontransformed mouse epidermal cells (Huang
et al., 1997). Thus, while the antiproliferative effect of aspirin
was demonstrated against three types of transformed cells
(colon, prostate and melanoma), the drug does not affect the
proliferation of nontransformed epidermal cells, nor does
salicylic acid affect the viability or proliferation of normal
activated human blood lymphocytes (Fingrut & Flescher,
2002). While aspirin was cytostatic to melanoma cells, it did
not kill these cells, similar to its effect on colon and prostate
carcinoma cells (Rotem et al., 2000; Shiff et al., 1996). On the
other hand, in combination with BCNU, aspirin enhanced B16
cell death. Thus, the type of effect of aspirin on the cells
(suppression of proliferation versus death) depends on the
context, that is, whether BCNU is present. BCNU was found
to enhance the activities of JNK and p38 in T lymphocytes
(Hehner et al., 2000). We hypothesize that these activities play
a role in the cytocidal effect of BCNU towards melanoma cells,
and that aspirin (by inducing these activities in B16 cells)
primes the cells to the cytotoxic action of BCNU, resulting in a
synergistic effect of aspirin and BCNU. Whereas aspirin
suppressed B16-F10.9 cellular proliferation at clinically
relevant concentrations (Katzung, 1998), the proliferation of
canine melanoma cells was only suppressed at levels of aspirin
that are not achievable in vivo (Knapp et al., 1995).
This different response results probably from interspecies
variation.
Aspirin induced p38 activation and JNK activity. A specific
p38 inhibitor – SB203580 (Lee et al., 1994; Turchi et al., 2000),
did not affect the suppressive activity of aspirin on B16
proliferation. On the other hand, SB202190 that inhibits both
p38 and JNK (Turchi et al., 2000), decreased the ability of
aspirin to suppress proliferation and to induce JNK activity in
B16 cells. Therefore, we conclude that JNK mediates the
suppressive effect of aspirin on B16 proliferation. Evidence for
the ability of p38 to mediate the response to cellular damage
has been demonstrated in a variety of cells exhibiting apoptotic
death. These include neurons (Horstman et al., 1998), PC-12
pheochromocytoma cells (Xia et al., 1995; Kummer et al.,
1997), rat and human fibroblasts (Kummer et al., 1997;
Schwenger et al., 1997), cardiac muscle cells (Wang et al., 1998;
Ma et al., 1999) and artery endothelial cells (Yue et al., 1999).
Also, p38 mediated suppression of proliferation in melanoma
cells, induced by a-melanocyte-stimulating hormone (Smalley
& Eisen, 2000, 2002a), IL-1 (Itoh et al., 1999) and TNF
(Hattori et al., 2001). However, p38 did not mediate salicylate-
induced apoptosis in leukemia cells (Hall et al., 2001), in
accordance with our findings. Moreover, inhibition of p38
increased farensyl thiosalicylic acid-induced apoptosis in Colo
853 melanoma cells (Smalley & Eisen, 2002b). Thus, whether
p38 mediates the perturbation of normal cellular functioning
or not, depends on the exogenous stimulus. Vitamin D may
induce apoptosis through various pathways including JNK,
and it has been shown to suppress the proliferation of
malignant melanoma cells (Osborne & Hutchinson, 2002),
pointing towards a possible connection between JNK activity
and a decrease in melanoma cellular proliferation, following
treatment with vitamin D. Our findings with aspirin provide
evidence for the plausibility of this possibility. The mechanism
underlying the effect of JNK on B16 cellular proliferation is
yet to be elucidated. The downstream effects of JNK include
activation of protein kinases and transcription factors,
including AP-1 (Whitmarsh & Davis, 1996). The identified
JNK substrates and genes they control are plausible targets for
a research effort aiming at analyzing the pathway through
which JNK activation results in suppression of cellular
proliferation.
While we studied the effect of aspirin up to 5mm, the highest
clinically relevant concentration of plasma salicylate is 3mm.
Higher levels cause various degrees of intoxication (Katzung,
1998). Since aspirin at 3mm caused approximately 30%
suppression of B16 proliferation, we assessed whether this
effect would increase over time and found it to be the case
(Figure 5). If one assumes that every day of exposure to aspirin
reduces cellular proliferation by 30%, the residual proliferative
potential after 3 days would be 0.7 0.7 0.7¼ 0.34. This is in
close agreement to the 37.3% of cellular proliferation that we
measured after 3 days of aspirin treatment (Figure 5). These
results fit the hypothesis that aspirin reduces the number of
cells in the population at the same rate each day. Thus, aspirin
treatment over time would decrease the total number of
melanoma cells very significantly. The issue of aspirin stability
in vitro and in vivo deserves consideration. The half-life of
aspirin in aqueous solution at 371C and pH 7 is about 20 h
(Connors et al., 1979). Hydrolysis of aspirin leads to the
generation of salicylic acid (Connors et al., 1979). In the
plasma, the half-life of aspirin is about 15min, while that of
salicylic acid can be up to about 12 h at antiinflammatory
dosage (Katzung, 1998). Since we found (Ordan & Flescher,
preliminary observations) that salicylic acid is as effective in
suppressing the proliferation of melanoma cells as aspirin, we
propose that aspirin and its major metabolite salicylic acid are
present at relevant levels for periods much longer than those
derived solely from the half-life of aspirin. Nevertheless, both
in vitro, and even more so in vivo, the relevant levels cannot last
for 3 days. Therefore, we propose an explanation based on the
following: SB202190 can be removed after the first 2 h of
exposure to aspirin and still be effective in decreasing the effect
of aspirin on proliferation (Figure 3). Thus, it appears that
while JNK mediates the suppressive effects of aspirin within
2 h postexposure (when the effective concentrations of aspirin
and salicylic acid are still very high) additional events (which
occur later, when lower concentrations of aspirin and salicylic
acid prevail) are instrumental in mediating the effect of aspirin
on melanoma cells. In other words, the high concentrations of
the drug are only required during the early period of exposure,
while lower concentrations of aspirin and its major metabolite
salicylic acid are sufficient to further suppress the proliferation
of melanoma cells. As for the practical ability to prolong the
period during which high concentrations of aspirin and
salicylic acid occur in vivo (where the half-life of aspirin is
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much shorter than in vitro), it can be achieved by daily
administration of aspirin at antiinflammatory dosage. Finally,
the synergism between aspirin and BCNU suggests that aspirin
may enhance the effects of chemotherapeutic drugs, and
possibly allow for the administration of the latter at lower (and
less toxic) levels than are currently used. We are initiating the
assessment of the therapeutic potential of aspirin by evaluating
the effect of treatment with aspirin, with and without
chemotherapeutic drugs, in vivo on the growth of B16 cells in
syngeneic mice.
In conclusion, our results indicate that aspirin suppresses the
proliferation of metastatic B16 melanoma cells in a JNK-
dependent mechanism.
This work was supported by the Israel cancer association and by the
Nofar program of the Israeli ministry of industry and trade.
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